Clinical Trials

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06369259 2026-04-01

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

33 enrolled

Advanced Colorectal Cancer

NCT05200442 2026-03-30

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

53 enrolled

Colorectal Neoplasms

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

27 enrolled

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT07411599 2026-03-12

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

28 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colorectal Cancer, Hereditary Nonpolyposis, Type 6, Carcinoma, Colorectal Neoplasms

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Colonic Neoplasms

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

24 enrolled 14 charts

Colonic Neoplasms

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

31 enrolled

Phase 1 Active not recruiting

Colorectal Neoplasms

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

24 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT07404527 2026-02-13

Bioelectrical Impedance Analysis for Perioperative Fluid Evaluation in Colorectal Cancer Surgery

Phase NA Recruiting

60 enrolled

Digestive System Neoplasms, Gastrointestinal Neoplasms

NCT03693807 2026-02-06

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

35 enrolled 14 charts

Colorectal Neoplasms, Cholangiocarcinoma

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

42 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT07389265 2026-02-05

CAPRI-3 GOIM

Phase 3 Recruiting

480 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT07381764 2026-02-02

ROMANCE - GOIM

150 enrolled

Colorectal Neoplasms

NCT05040568 2026-01-26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1 Completed

15 enrolled

Phase 2/3 Active not recruiting

Colonic Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Colonic Neoplasms

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

42 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

12 enrolled

Phase 4 Not yet recruiting

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Colorectal Neoplasms

NCT03290937 2026-01-06

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1 Completed

34 enrolled

Colorectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Colorectal Cancer Metastatic

NCT06578559 2026-01-05

BRICKET

16 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

46 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Colorectal Cancer Metastatic

NCT05959356 2025-12-17

CEIL

198 enrolled

Colorectal Neoplasms

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

40 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

43 enrolled

Colorectal Neoplasms

NCT05510895 2025-10-01

NeoBRAF

2 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT07183865 2025-09-19

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

44 enrolled

Phase 1 Active not recruiting

Locally Recurrent Rectal Cancer

NCT01787500 2025-09-09

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

33 enrolled

Noonan syndrome 3, Neoplasm Metastasis, Colorectal Neoplasms

NCT05775900 2025-09-03

Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer

Phase 1/2 Completed

24 enrolled

Colorectal Neoplasms

NCT05706779 2025-09-02

NEORAF

30 enrolled

GastrointestinalGynecologic

Colorectal Neoplasms

NCT00766142 2025-08-29

COCHISE

Phase 2 Terminated

18 enrolled 9 charts

Colonic Neoplasms, Peritoneal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

146 enrolled

Colorectal Neoplasms

NCT03186326 2025-06-29

SAMCO

132 enrolled

Colorectal Neoplasms

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Phase 1/2 Recruiting

64 enrolled

Colorectal Cancer Metastatic

NCT04554836 2025-06-08

MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

6 enrolled 9 charts

Phase 3 Not yet recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT07004413 2025-06-04

FIRE-11

267 enrolled

Colorectal Neoplasms

NCT05312398 2025-05-25

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

219 enrolled

Metastatic Colorectal Adenocarcinoma

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

64 enrolled

Neoplasms, Colorectal Neoplasms

NCT06908031 2025-05-14

CRIT

49 enrolled

Rectal Neoplasms

NCT04853043 2025-05-06

APK Mutant

Phase 2 Terminated

7 enrolled 15 charts

Colorectal Neoplasms

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Colonic Neoplasms, Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

673 enrolled

Colorectal Neoplasms

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT06763029 2025-02-27

VICPROIRI

36 enrolled